Biomarin Pharmaceutical (BMRN) Deferred Taxes (2010 - 2026)

Biomarin Pharmaceutical (BMRN) has 17 years of Deferred Taxes data on file, last reported at $9.2 million in Q1 2026.

• Quarterly Deferred Taxes fell 67.57% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (down 64.95% YoY) and the FY2025 annual result came in at $48.7 million, down 13.12% from the prior year.
• Deferred Taxes rose to $9.2 million in Q1 2026, from $613000.0 in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $42.4 million in Q4 2024 to a low of -$51.3 million in Q4 2022.
• A 5-year average of $999176.5 and a median of $613000.0 in 2025 frame the typical range for Deferred Taxes.
• Annual changes were most pronounced in 2022 — Deferred Taxes plunged 1330.99% — and 2025, when it surged 9875.09%.
• Tracing BMRN's Deferred Taxes over 5 years: stood at -$51.3 million in 2022, then soared by 51.61% to -$24.8 million in 2023, then surged by 270.61% to $42.4 million in 2024, then tumbled by 98.55% to $613000.0 in 2025, then surged by 1404.08% to $9.2 million in 2026.
• The last three Deferred Taxes figures came in at $9.2 million (Q1 2026), $613000.0 (Q4 2025), and -$13.6 million (Q3 2025), per Business Quant data.